Gene expression profiling in primary AML cells treated with decitabine and cytarabine

ABSTRACT: Acute myeloid leukemia (AML), and other myeloid malignancies, are frequently treated with hypomethylating agents like decitabine. Alterations in the epigenome, induced by decitabine, are likely to result in gene expression changes. The effects of decitabine have not been systemically studied using primary AML samples.

ORGANISM(S): Homo sapiens

PROVIDER: GSE40442 | GEO | 2012/12/18

SECONDARY ACCESSION(S): PRJNA174047

REPOSITORIES: GEO